# A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

> **NCT05242822** · PHASE1 · TERMINATED · sponsor: **Kinnate Biopharma** · enrollment: 54 (actual)

## Conditions studied

- Solid Tumor, Adult
- Intrahepatic Cholangiocarcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** KIN-3248

## Key facts

- **NCT ID:** NCT05242822
- **Lead sponsor:** Kinnate Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-29
- **Primary completion:** 2024-10-03
- **Final completion:** 2024-10-03
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor prior to enrollment into the dose expansion part of the study (Part B).
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242822, "A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05242822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*